Modified Intermediate-Dose Cytarabine Combined with Daunorubicin Induction and Re-Induction Protocol Use in Patients with Acute Myeloid Leukemia
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 4
Abstract
Background A prospective study was conducted to investigate the response rate of patients newly diagnosed with acute myeloid leukemia (AML) to modified intermediate-dose cytarabine with daunorubicin. Methods A total of 45 patients received cytarabine at a modified intermediate-dose (115 mg/m<sup>2</sup>) given by continuous intravenous infusion for 12 hours twice daily over 7 days and daunorubicin 45 mg /m<sup>2</sup> given on days 1, 2, and 3 of induction therapy. Patients with a complete response received reinduction with cytarabine at the same dose and infusion over 5 days with 2 doses of daunorubicin. After remission, patients who were socioculturoeconomically eligible for transplantation were evaluated for other prognostic factors, except for cytogenetic factors that were not available in the study center, to identify patients that were eligible for stem cell transplantation. Results Patients were 17 to 60 years of age. 6 patients had early death due to complications and treatment failure. 39 patients (87%) achieved complete remission. Only 16 patients were eligible for transplantation on evaluation and underwent allogeneic stem-cell transplantation. 18 patients were not eligible for this transplantation and underwent consolidation therapy with chemotherapy. 5 patients did not receive any treatment and died during the follow up. In the follow up period between April 2006 and January 2014 in 39 out of 45 patients (min 0.2 yr, max 7. 8 yr) 31 % of patients were alive. Conclusions Modified intermediate dose cytarabine was effective for the treatment of AML, achieving a high rate of complete remission, and might improve outcomes in patients.
Authors and Affiliations
Mozaffar Aznab, Omid Beiki
Keywords
Related Articles
- EP ID EP237355
- DOI 10.5812/ijcm.7000
- Views 73
- Downloads 0
Seroprevalence of Cytomegalovirus Antibodies and Primary Infection amongWomen and Infants in Iran: A Meta-Analysis
Background: Seroprevalence of Cytomegalovirus infection varies between 40% and 100% worldwide. Different studies carried out in Iran indicate this variation in this country. It is important to estimate the total infectio...
Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors
Background: Human epidermal growth factor receptor 2 (HER2) overexpression and amplification have been studied as a therapeutic and prognostic target in a number of tumors although conflicting data exist about the incide...
Cannabis sativa Extract Reduces Cytoskeletal Associated Proteins in Breast Cancer Cell Line
Background: Previous studies suggested that Cannabis sativa has anti-cancer properties influencing tumor size and metastasis properties. Microtubule associated proteins (MAPs) such as tau binds to the microtubules and le...
No Association Between Human Papillomavirus and Prostate Cancer
Background: The role of human papillomavirus (HPV) in prostate cancer is unclear. The aim of this study was to investigate the relationship between HPV and prostate cancer. Methods: In this case - control study, 133 par...
Efficacy of Acceptance and Commitment Therapy on Breast Cancer Female Patients’ Hope
Background Breast cancer is one of the most serious diseases that can endanger physical, psychological, and social health of women suffering from this disease. Objectives The aim...